Explore

Program Map

Start with a treatment, device, company, diagnosis, or trial ID. Each record keeps the source trail close to the claim.

161Main(26 active)

148Status checked

135Strong

320Backlog

More filters and sort (2 active)

Company-led only

2 records in Main database · 1 strong · 2 status checked

Compare	Program	Company	Type	Product	Modality	Stage	Status	Reliability	Evidence	Conf.	Population	Indications	Inspect
Add	Otarmeni by Regeneron	Regeneron Pharmaceuticals	Therapeutic	-	Gene Therapy	Approved	Approved	Details checkedStrong evidence	regulatory · Priority 1	99%	PediatricAdult+6	Hearing LossSensorineural Hearing Loss+3
Add	DB-020 by Regeneron and Decibel	Regeneron Pharmaceuticals	Therapeutic	-	Drug Delivery	Phase 1	Completed	Details checkedStatus confirmedHistorical/discontinued	publication · Priority 2	92%	AdultCisplatin Ototoxicity	Cisplatin-Induced Hearing LossHearing Loss